Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul Ross, Vincenzo Mazzaferro, Jean-Frédéric Blanc, Yuk Ting Ma, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean-François Dufour, Edward J Gane, Baek-Yeol Ryoo, Markus Peck-Radosavljevic, Thong Dao, Winnie Yeo, Wisut LamlertthonSatawat Thongsawat, Michael Teufel, Katrin Roth, Diego Reis, Barrett H Childs, Heiko Krissel, Josep M Llovet

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences